Trials / Not Yet Recruiting
Not Yet RecruitingNCT07136558
Evaluation of ICP-B794 in Patients With Advanced Solid Tumors
An Open-Label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ICP-B794 in Patients With Advanced Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 410 (estimated)
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
An Open-Label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ICP-B794 in Patients with Advanced Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ICP-B794 | Intravenous administration once every 3 weeks |
Timeline
- Start date
- 2025-08-01
- Primary completion
- 2029-06-01
- Completion
- 2030-12-01
- First posted
- 2025-08-22
- Last updated
- 2025-08-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07136558. Inclusion in this directory is not an endorsement.